Lotus Blooms in Hyderabad: Rs 36 Crore R&D Hub Launched

Lotus, a publicly listed pharmaceutical company on the Taiwan Stock Exchange, is set to expand its research and development capabilities with the establishment of a new center in Hyderabad. The company has launched a subsidiary, Meishi Pharma Services, with an investment of Rs 36 crore.

The proposed 20,000 sq. ft. center will be located in Genome Valley and is expected to employ around 100 individuals. The development will occur in two phases: Phase 1 is set to become operational by Q2 2025, while Phase 2 will be completed by Q4 2025. This center will focus on pharmaceutical formulation development, analytical research, intellectual property management, clinical project management, and other related research functions.

Meishi Pharma Services is committed to collaborating with local institutions and industry leaders to foster innovation. The company plans to invest in advanced technologies and build a skilled workforce, further cementing Hyderabad’s position as a global life sciences hub. Through its strategic initiatives, Meishi Pharma Services seeks to contribute to the growth of the life sciences sector and drive innovation in the region.

News by Rahul Yelligetti.